Long-term outcomes of primary biliary cholangitis in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective-prospective multicenter cohort enrolling roughly 4,000 PBC patients from ten centers across China, led by Beijing Friendship Hospital. Investigators will collect baseline clinical and laboratory data and perform longitudinal follow-up to record survival, disease progression, and treatment changes. Analyses will examine the effects of symptoms, disease stage, biochemical response to ursodeoxycholic acid (UDCA), and use of second-line therapies on long-term outcomes. The study excludes patients with other chronic liver diseases, active malignancy, or severe comorbidities and aims to generate prognostic models tailored to the Chinese population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis consistent with PBC.
* Willingness to participate, with informed consent obtained from the patient or legal representative (if the patient is deceased or cognitively impaired), and ability to adhere to follow-up.

Exclusion Criteria:

* Co-existing chronic hepatitis B or C, drug-induced liver injury, autoimmune hepatitis, primary sclerosing cholangitis, or hereditary/metabolic liver diseases.
* Co-existingMalignancy or severe cardiac, pulmonary, renal, cerebral, or hematologic disorders expected to substantially shorten life expectancy.
* Incomplete baseline medical records or laboratory data.

Where it's running

• Liver Research Center, Beijing Friendship Hospital, Capital Medical University
  Beijing, Select A State Or Province, China Recruiting

Study contacts

• Study coordinator: Jidong Jia
• Email: jia_jd@ccmu.edu.cn
• Phone: +86-10-63139246

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-Term Recovery and Quality of Life after Sepsis in ICUs

  This international study follows adults with sepsis in ICUs to see how their quality of life and other outcomes look six months later.

  Recruiting University of Geneva, Switzerland · Geneva · NCT07863128

• Cardiac MRI-based prediction tool for outcomes in dilated cardiomyopathy

  This project will test whether adding multi-parameter stress perfusion cardiac MRI to routine clinical data can better predict which people with dilated cardiomyopathy will go on to develop heart failure, arrhythmias, hospitalizations, or death.

  Recruiting Shandong Provincial Hospital · Jinan, Shandong · NCT07527715

• Biochemical response and health outcomes in people with primary biliary cholangitis

  We will follow adults with primary biliary cholangitis who are taking ursodeoxycholic acid (UDCA) to see if their alkaline phosphatase levels after treatment predict how long they stay free of complications.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07449793

• Fenofibrate versus UDCA for first-line treatment of primary biliary cholangitis

  This study will test whether fenofibrate works better than the standard medicine UDCA for adults with newly diagnosed primary biliary cholangitis who have not been treated before.

  Recruiting at 2 sites Phase 3 Xijing Hospital of Digestive Diseases · Guangzhou, Guangdong and 1 other locations · NCT07296458

• Early detection of primary biliary cholangitis in people with positive AMA and normal ALP

  This project will test whether clinical features, blood markers, or a liver biopsy can identify early PBC in adults (18-80) who have positive AMA but normal ALP.

  Recruiting Hospital Universitario La Paz · Madrid · NCT07205874

• Multimodal prehabilitation to reduce fatigue in primary biliary cholangitis

  This trial will try a combined program of supervised exercise, nutritional counseling, and mindfulness to reduce fatigue in adults with primary biliary cholangitis who have moderate-to-severe fatigue.

  Recruiting Hospital Clinic of Barcelona · Barcelona, Barcelona · NCT07161245

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.